Sotrovimab retains activity against SARS-CoV-2 omicron variant BQ.1.1 in a non-human primate model

The SARS-CoV2 Omicron variants have acquired new Spike mutations leading to escape from the most of the currently available monoclonal antibody treatments reducing the options for patients suffering from severe Covid-19. Recently, both in vitro and in vivo data have suggested that Sotrovimab could r...

Descripción completa

Detalles Bibliográficos
Autores principales: Hérate, Cécile, Marlin, Romain, Touret, Franck, Dereuddre-Bosquet, Nathalie, Donati, Flora, Relouzat, Francis, Junges, Laura, Galhaut, Mathilde, Dehan, Océane, Sconosciuti, Quentin, Nougairède, Antoine, de Lamballerie, Xavier, van der Werf, Sylvie, Le Grand, Roger
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2023
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10228175/
https://www.ncbi.nlm.nih.gov/pubmed/37287613
http://dx.doi.org/10.1016/j.heliyon.2023.e16664
Descripción
Sumario:The SARS-CoV2 Omicron variants have acquired new Spike mutations leading to escape from the most of the currently available monoclonal antibody treatments reducing the options for patients suffering from severe Covid-19. Recently, both in vitro and in vivo data have suggested that Sotrovimab could retain partial activity against recent omicron sub-lineage such as BA.5 variants, including BQ.1.1. Here we report full efficacy of Sotrovimab against BQ.1.1 viral replication as measure by RT-qPCR in a non-human primate challengemodel.

Ejemplares similares